Press Room

Check Out the Latest News and Activities at Proteocyte.

Press Releases

Proteocyte Announces Mark Hammar as new CEO

Toronto, ON; January 19, 2022 - Proteocyte AI, a company dedicated to producing a range of technological solutions that predict a patient's risk of developing oral cancer, is pleased to announce the appointment of Mark Hammar as Chief Executive Officer, effective immediately. Mr. Hammar is taking...

read more

Proteocyte Selects Medlior as Health Outcomes Research Provider

MaRS Discovery District, Toronto, ON; December 1, 2021 - Proteocyte AI is pleased to announce its formal engagement with Medlior, a health outcomes research provider based in Calgary, Alberta. Proteocyte will rely on Medlior's team of diverse subject matter experts to bring scientific expertise,...

read more

Select Presentations

1. Hwang, Jason TK et al., A novel prognostic assessment for identifying oral pre-malignant lesions at high risk for progression to cancer. September 18-23, 2016. AAOMS Annual Meeting, Las Vegas, NV, USA

2. Ralhan, R et al. Early detection of oral lesions with dysplasia at high risk of cancer development using a proteomic signature image analysis based Straticyte test. Mar. 4 – 6, 2016. The Global Oral Cancer Forum, NY, USA.

3. Ralhan, R et al. A proteomic signature image analysis based test for predicting risk of cancer development in oral lesions with dysplasia. Feb. 26 – 28, 2016. Tata Memorial Centre Platinum Jubilee – A Conference of new ideas in Cancer. Mumbai, India.

4. Ralhan, R et al. Predicting risk of cancer development in oral lesions with dysplasia using Straticyte. Feb. 23 – Mar. 2, 2016. MedTech Mission to India: MolQ Diagnostics (Guragon); Sapien Biosciences (Hyderabad); Tata Memorial Hospital (Mumbai); ONCQuest Lab and All India Institute of Medical Sciences (New Delhi); Institute of Cytology and Preventive Oncology (Noida).

5. Ralhan, R et al. Prognostic significance of head and neck cancer biomarkers: translation into oral surgery clinics. Sept. 2015. HUPO. Vancouver, Canada.

6. Ralhan, R. Straticyte is an image analysis based prognostic test for oral dysplasia. Jul. 8 – 11, 2015. 5th World IAOO Congress. Sao Paulo, Brazil.

7. Kaur, J et al. Molecular signature for predicting risk of cancer development in oral lesions with dysplasia. Apr. 25 – 30, 2014. Annual Conference of the Academy of Oral and Maxillofacial Pathology. St. Augustine, USA.

8. Ralhan, R. Prognostic markers for oral cancer. Feb. 23, 2012. HNC Translational Research Meeting. UHN, Toronto, Canada.

9. Matta, A et at. Proteomics based prognostic signature of head and neck cancer. May 9 -11, 2011. Canadian National Proteomics Network Symposium. Banff, Canada.

Select Publications

1. Hwang, Jason T.K et al. Individualized five-year risk assessment for oral premalignant lesion progression to cancer. March 2017. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology. Vol. 123, Issue 3, Pages 374-381.

2. Chauhan, SS et al. Prediction of recurrence-free survival using a protein expression-based risk classifier for head and neck cancer. 2015. Oncogenesis. doi: 10.1038/oncsis.2015.7

3. Kaur, J et al. S100A7 overexpression is a predictive marker for high risk of malignant transformation in oral dysplasia. 2013. Int J Cancer. doi: 10.1002/ijc.28473

4. Tripathi, SC et al. Nuclear S100A7 is associated with poor prognosis in head and neck cancer. 2010. PLoS One. doi:

Sign up, read up, stay informed!

Join our mailing list to stay up-to-date with the latest news and activities from Proteocyte.

Thank you for subscribing to our newsletter!